10.12.19: Investor Conference Call: Bayer 2030 Sustainable Development Objectives
Investor Conference Call: Bayer 2030 Sustainable Development ObjectivesLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 27, 2019 Category: Pharmaceuticals Source Type: news
12.12.19: Citi Global Healthcare Conference, New York, U.S.A.
Citi Global Healthcare Conference, New York, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 27, 2019 Category: Pharmaceuticals Source Type: news
25.11.19: Not intended for U.S. and UK Media
Bayer submits application to EMA for use of rivaroxaban in children with venous thromboembolismAdding treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children from birth to 17 years of age with confirmed VTE, including cerebral vein and sinus thrombosis / Submission based on results from phase 3 EINSTEIN-Jr. study showing convincing efficacy and safety profile for rivaroxaban in children with VTE / An oral liquid formulation of rivaroxaban that does not require injections and regular monitoring was developed to facilitate pediatric administration / Patent extension in Europe of six months will...
Source: Bayer IR Newsfeed: Events - November 25, 2019 Category: Pharmaceuticals Source Type: news
18.11.19: Not intended for U.S. and UK Media
Phase III VICTORIA study with vericiguat in patients with worsening chronic heart failure meets primary endpointVericiguat reduced the risk of cardiovascular death or heart failure hospitalization versus placebo when given in combination with available heart failure therapies / Vericiguat is the first-in-class soluble guanylate cyclase stimulator being developed to treat patients with worsening chronic heart failuremehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 19, 2019 Category: Pharmaceuticals Source Type: news
07.11.19: not for distribution in the united states of america, australia, canada, south africa or japan
Bayer refinances 1.75 billion euro hybrid bondNew issue of two tranches with a non-call period of 5.5 and 8 years combined with a tender offer for Bayer's existing hybrid bondmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 7, 2019 Category: Pharmaceuticals Source Type: news
10.12.19: Investor Conference Call to introduce Bayers Sustainability Strategy 2030
Investor Conference Call to introduce Bayers Sustainability Strategy 2030Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 6, 2019 Category: Pharmaceuticals Source Type: news
06.11.19: Roadshow Boston, U.S.A.
Roadshow Boston, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 5, 2019 Category: Pharmaceuticals Source Type: news
05.11.19: Roadshow Toronto / Chicago, U.S.A.
Roadshow Toronto / Chicago, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 4, 2019 Category: Pharmaceuticals Source Type: news
05.11.19: Roadshow London, UK
Roadshow London, UKLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 4, 2019 Category: Pharmaceuticals Source Type: news
04.11.19: Bayer completes sale of Dr. Scholl's™ brand to Yellow Wood Partners
Bayer completes sale of Dr. Scholl's™ brand to Yellow Wood Partnersmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 4, 2019 Category: Pharmaceuticals Source Type: news
04.11.19: Roadshow New York, U.S.A.
Roadshow New York, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 3, 2019 Category: Pharmaceuticals Source Type: news
04.11.19: Roadshow Frankfurt, Germany
Roadshow Frankfurt, GermanyLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 3, 2019 Category: Pharmaceuticals Source Type: news
04.08.20: Half-Year Report 2020
Half-Year Report 2020Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 30, 2019 Category: Pharmaceuticals Source Type: news
03.11.20: Q3 2020 Quarterly Statement
Q3 2020 Quarterly StatementLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 30, 2019 Category: Pharmaceuticals Source Type: news
30.10.19: Third quarter of 2019
Bayer: Encouraging business performance across all divisions - agreements signed to divest Currenta and Animal HealthGroup sales increase by 5.4 percent (Fx & portfolio adj.) to 9.830 billion euros / EBITDA before special items advances by 7.5 percent to 2.291 billion euros / Crop Science reports higher sales and substantial earnings growth / Pharmaceuticals increases sales - earnings decline due to one-time income in prior year / Consumer Health posts growth in sales (Fx & portfolio adj.) and earnings / Net income declines by 63.9 percent to 1.036 billion euros - substantial divestment gain included in prior year / Core e...
Source: Bayer IR Newsfeed: Events - October 30, 2019 Category: Pharmaceuticals Source Type: news
